Comprehensive analysis of macrosomia: exploring the association between first-trimester alanine aminotransferase and uric acid measurements in pregnant women
Author:
Arslanca Seyma Banu1ORCID, Caglar Ali Turhan1ORCID
Affiliation:
1. Department of Perinatology , Etlik City Hospital , Ankara , Türkiye
Abstract
Abstract
Objectives
Investigating the relationship between liver enzymes, uric acid (UA), and macrosomia will benefit physicians in the early detection of complications that may emerge during/after pregnancy. The study analyzed liver enzyme activity and UA levels in first-trimester pregnant for the risk of macrosomia.
Methods
This retrospective cross-sectional research analyzed the data of pregnant women who gave birth between Jan 2021–2023. All data were extracted from medical records, and UA and AST-ALT were examined in all the participants.
Results
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were higher in the macrosomia (p<0.05). Similarly, UA levels were higher in the macrosomia (p<0.001). There was a moderate positive correlation between ALT and birth weight (r=0.168, p<0.01), while we found a strong positive correlation between UA and birth weight (r=0.355, p<0.01). In the ROC (receiver operating characteristic), Area Under the Curve (AUC) for ALT and UA was significant (p<0.0001) but not for AST (p=0.157). UA showed a predictive value for macrosomia with 68.1 % sensitivity and 63.8 % specificity at a 3.15 cut-off (AUC:0.689; p:0.0001; CI:0.644–0.725).
Conclusions
These results indicate that ALT and UA may be potentially important in determining the risk of macrosomia. The UA had a more potent marker for macrosomia than ALT. The occurrence of macrosomia might be more closely related to the mother’s metabolic syndrome rather than NAFLD.
Publisher
Walter de Gruyter GmbH
Subject
Obstetrics and Gynecology,Pediatrics, Perinatology and Child Health
Reference27 articles.
1. Allen, AM, Therneau, TM, Larson, JJ, Coward, A, Somers, VK, Kamath, PS. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study. Hepatology 2018;67:1726–36. https://doi.org/10.1002/hep.29546. 2. Chalasani, N, Younossi, Z, Lavine, JE, Charlton, M, Cusi, K, Rinella, M, et al.. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328–57. https://doi.org/10.1002/hep.29367. 3. Hagström, H, Höijer, J, Ludvigsson, JF, Bottai, M, Ekbom, A, Hultcrantz, R, et al.. Adverse outcomes of pregnancy in women with non-alcoholic fatty liver disease. Liver Int 2016;36:268–74. https://doi.org/10.1111/liv.12902. 4. Ajmera, VH, Gunderson, EP, VanWagner, LB, Lewis, CE, Carr, JJ, Terrault, NA. Gestational diabetes mellitus is strongly associated with non-alcoholic fatty liver disease. Am J Gastroenterol 2016;111:658–64. https://doi.org/10.1038/ajg.2016.57. 5. Sarkar, M, Grab, J, Dodge, JL, Gunderson, EP, Rubin, J, Irani, RA, et al.. Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes. J Hepatol 2020;73:516–22. https://doi.org/10.1016/j.jhep.2020.03.049.
|
|